NCT05788289View on ClinicalTrials.gov

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Mantle Cell LymphomaMCL
Interventions
DRUG

Tafasitamab

Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.

DRUG

Lenalidomide

Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All protocol activities), Harrison

11553

Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (All protocol activities), Montvale

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER